11 Aug Vaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic Telangiectasia

Vaderis raises an oversubscribed $152M Series B to fund engasertib through FDA approval, as Phase 3 HEROIC begins for rare disease HHT....